Clinical Trials Logo

Filter by:
NCT ID: NCT05065164 Withdrawn - Denosumab Allergy Clinical Trials

Denosumab and Screw Fixation for Osteoporotic Compression Fracture

Start date: September 14, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

Evaluation of bone mineral density and function at 1 year after screw internal fixation of osteoporotic vertebral compression fractures with desuzumab: a parallel double-blind randomized controlled clinical trial

NCT ID: NCT05061277 Withdrawn - Healthy Clinical Trials

Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Recifercept in Healthy Chinese Participants

Start date: October 25, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the pharmacokinetic (PK), safety, tolerability and immunogenicity of a single subcutaneous (SC) dose of the lyophilized formulation of recifercept in healthy Chinese participants.

NCT ID: NCT05055817 Withdrawn - Clinical trials for Necrotizing Enterocolitis

a Clinical Risk Score to Predict Bloody Stool in Neonates

Start date: October 1, 2021
Phase:
Study type: Observational

Bloody stool is a main focus in non-neonatal intensive care unit ward, and it is one of the risk factors in neonates with subsequent necrotizing enterocolitis(NEC) and usually lead to longed duration of hospitalization. NEC is one of the most serious disease in the newborn infants, and two and more grades of NEC might lead to surgery, even death. But, it is difficult to predict when the bloody stool comes and develop to two and more grades of NEC.

NCT ID: NCT05053269 Withdrawn - Clinical trials for Bronchopulmonary Dysplasia

Body Weight Growth After Birth and Bronchopulmonary Dysplasia

Start date: October 1, 2021
Phase:
Study type: Observational

Bronchopulmonary dysplasia (BPD) is one of the most common, complex, and severe diseases in preterm infants. BPD was first described as chronic pulmonary disease in survivors of severe respiratory distress syndrome (RDS) in 1967, which was also called as the "old" BPD. In recent years, the definition for BPD has developed a lot. The National Institute of Child Health and Human Development (NICHD) workshop in 2018 assessed BPD at 36 post-menstrual age (PMA) along with radiographic confirmation and used a severity grading of I-III. Although with effective surfactant supplement and oxygen support, BPD brings a great challenge to neonatologists.

NCT ID: NCT05039931 Withdrawn - Breast Cancer Clinical Trials

A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Solid Tumors

Start date: September 15, 2021
Phase: Phase 1
Study type: Interventional

In this study, the safety, tolerability and preliminary effectiveness of GNC-035 in participants with locally advanced or metastatic solid tumors will be investigated to assess the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) or maximum administered dose (MAD) for MTD is not reached of GNC-035.

NCT ID: NCT05033132 Withdrawn - Cervical Cancer Clinical Trials

A Phase II Study of Balstilimab Independently or in Combination With Zalifrelimab in Advanced Cervical Cancer

Start date: October 1, 2021
Phase: Phase 2
Study type: Interventional

This is an open-label, multi-center Phase II clinical trial to assess the efficacy, safety, and pharmacokinetics of Balstilimab (Treatment Arm 1 - monotherapy) or in combination with Zalifrelimab (Treatment Arm 2 - combination therapy) for treatment of patients with advanced cervical cancer who relapsed or progressed after receiving first-line platinum-based chemotherapy.

NCT ID: NCT05019677 Withdrawn - Clinical trials for Intrahepatic Cholangiocarcinoma

GP Chemotherapy in Combination With Tislelizumab and Ociperlimab as First-line Treatment in Advanced BTC

Start date: September 1, 2021
Phase: Phase 2
Study type: Interventional

This is an open label, multi-center, phaseâ…¡study to evaluate the efficacy and safety of GP (Gemcitabine/Cisplatin) in combination with Tislelizumab and Ociperlimab as first-line treatment in participants with unresectable advanced Biliary Tract Carcinoma (BTC).

NCT ID: NCT05015972 Withdrawn - B-cell Lymphoma Clinical Trials

UCAR-T for CD19+ Refractory/Relapsed B Hematologic Malignancies

Start date: August 20, 2021
Phase: Early Phase 1
Study type: Interventional

This is a single arm, open-label, single-center prospective study to determinethe safety and efficacy of CTA30X UCAR-T cells in patients diagnosed with CD19+ refractory/relapsed B Hematologic Malignancies

NCT ID: NCT05001360 Withdrawn - Clinical trials for Gastric Adenocarcinoma

Study of FMT Combined With Nivolumab in Gastric Cancer

Start date: October 2021
Phase: N/A
Study type: Interventional

This study is a single-arm, single center study. The purpose of this study is to evaluate the efficacy and safety of FMT capsules XBI-302 combined with Nivolumab in the treatment of anti-PD-1/L1 resistant gastric cancer.

NCT ID: NCT04991779 Withdrawn - Neonatal Seizure Clinical Trials

AI-assisted cEEG Diagnosis of Neonatal Seizures in Neonatal Intensive Care Unit

Start date: March 16, 2022
Phase:
Study type: Observational

A diagnostic accuracy study on Artificial intelligence assisted continue EEG diagnostic tool is to carried out comparing with manually EEG interpretation as the golden standard for neonatal seizure.